Arovella Therapeutics Stock Forecast for 2023 - 2025 - 2030

Arovella Therapeutics Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Arovella Therapeutics's Revenue has grown, moving from $1.25M to $1.45M – an increase of 16.00%. In the next year, analysts predict that Revenue will jump to $2.31M – up 58.98% from the current level. Looking ahead to seven years, experts forecast that Revenue will grow by 55.62%.

Arovella Therapeutics Dividend per Share Forecast for 2023 - 2025 - 2030

Arovella Therapeutics Free Cash Flow Forecast for 2023 - 2025 - 2030

Arovella Therapeutics EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, EBITDA for Arovella Therapeutics has grown by 115.40%, going from $-3.96M to $-8.53M. For the next year, 0 analysts project Arovella Therapeutics's EBITDA to drop by 19.22%, reaching $-6.89M. By 2030, professionals believe that Arovella Therapeutics's EBITDA will decrease by 21.51%, reaching $-6.70M – a concerning trend for the company.

Arovella Therapeutics EBIT Forecast for 2023 - 2025 - 2030

Arovella Therapeutics's EBIT has grown in the last three years, jumping from $-4.11M to $-8.63M – an increase of 109.98%. According to 0 prominent analysts, Arovella Therapeutics's EBIT will fall by 18.68% in the next year, reaching $-7.02M. By 2030, professionals believe that Arovella Therapeutics's EBIT will decrease by 20.97%, reaching $-6.82M – a concerning trend for the company.

Arovella Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last four years, Arovella Therapeutics's EPS has grown, moving from $-0.03 to $0.00 – an increase of 100.00%. In the next year, analysts predict that EPS will jump to $0.00 – up 100.00% from the current level. Looking ahead to six years, experts forecast that EPS will grow by 100.00%.